news

Daiichi Sankyo expands access to its clinical trial data

0
SHARES

Posted: 2 February 2016 | | No comments yet

Daiichi Sankyo has announced that it will share its clinical trial data to qualified researchers through the clinicalstudydatarequest.com system…

Lixiana

Daiichi Sankyo has announced that it will share its clinical trial data to qualified researchers through the clinicalstudydatarequest.com system.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

clinical trial data

Beginning today, qualified researchers may submit research proposals to clinicalstudydatarequest.com requesting data from Daiichi Sankyo-sponsored trials for approved medicines in the EU and US.  Daiichi Sankyo will provide data for approved medicines and indications from 01 January 2014 onward.  Access is mediated by an independent review panel.  

“Sharing clinical data from trials sponsored by Daiichi Sankyo with qualified researchers helps foster additional scientific insights and provides a mechanism for further understanding of our medicines, which ultimately is a benefit to patient healthcare” says Mahmoud Ghazzi, MD, PhD, Global Head of Development for Daiichi Sankyo.

Once a qualified request is approved by the independent panel, and deemed clear of restrictions, Daiichi Sankyo will anonymise the information to protect patient privacy, and will make requested analyses available in a secure electronic environment.  Daiichi Sankyo will ensure all applicable laws and regulations are adhered to throughout this process. 

Daiichi Sankyo registers clinical trials and discloses clinical trial results according to all local and regional laws and requirements. As Daiichi Sankyo is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA), this initiative is also consistent with the EFPIA-PhRMA Principles for Responsible Clinical Trial Data Sharing.

Related topics

Related organisations

Share via
Share via